756PInterim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations. (23rd October 2018) - Hollebecque, A; Borad, M; Sahai, V; Catenacci, D V T; Murphy, A; Vaccaro, G; Paulson, A; Oh, D-Y; Féliz, L; Lihou, C; Zhen, H; Abou-Alfa, G K